Introduction
============

Efflux of cytotoxic drugs by the adenosine 5′-triphosphate--binding cassette transporter subfamily B member 1 (ABCB1 aka multidrug resistance protein 1 \[MDR1\]/P-glycoprotein) is considered a potential mechanism of acquired chemoresistance to antineoplastics.[@b1-bctt-9-415] However, there is a controversy regarding the role of *ABCB1* expression in breast cancer.[@b2-bctt-9-415],[@b3-bctt-9-415] Literature discrepancies may involve the lack of standardized methods for the detection and quantification of ABCB1 in solid tumors.[@b4-bctt-9-415] For instance, there is a long-lasting notion of uncertainty regarding ABCB1 detection due to the lack of sensitivity and/or specificity of several commercial ABCB1 antibodies.[@b2-bctt-9-415],[@b5-bctt-9-415],[@b6-bctt-9-415] In addition, there seems to be great interpatient variability.[@b3-bctt-9-415] One possible reason for such variability is that the *ABCB1* gene is polymorphic, and two of its single-nucleotide polymorphisms (SNPs), rs1128503 and rs1045642, may modify the final protein conformation, compromising its membrane stability and substrate recognition.[@b7-bctt-9-415],[@b8-bctt-9-415] Finally, it has been reported that the *ABCB1* expression may also be modulated by plasma aldosterone[@b9-bctt-9-415] or cortisol,[@b10-bctt-9-415] as well as by dietary salt and dehydration.[@b9-bctt-9-415]

In this study, a systematic evaluation of *ABCB1* expression in the breast, encompassing benign lesions, breast tumors examined prior to any chemotherapeutic treatment and nonmalignant mammary tissues adjacent to breast tumors, was done. The study was conducted in a prospective manner by using the tissue samples from a cohort of 712 Brazilian women who underwent curative mammary surgery. *ABCB1* expression was estimated by immunohistochemistry with three previously validated antibodies, and its association with clinical and histopathological variables, including the genetic profile regarding *ABCB1* SNP, was evaluated. Finally, the impact of *ABCB1* expression on short-time (2-year) disease-free survival of patients with breast cancer was also investigated.

Methods
=======

Subjects and study design
-------------------------

The study population was a prospective cohort of Brazilian women who were admitted from January 2009 to December 2012 at Instituto Nacional de Câncer (INCA) for mammary surgery. The exclusion criteria were the following: any previous oncological treatment, prior contralateral or bilateral synchronous breast cancer, and systemic metastasis at diagnosis. [Figure 1](#f1-bctt-9-415){ref-type="fig"} illustrates the flowchart of the study design, depicting the reasons for exclusion and the sample availability for each analysis.

The study protocol (approved by the Ethics Committee of INCA \#129/08) did not interfere with the routine clinical follow-up or therapeutic choice. All the patients provided written informed consent to be enrolled in the present study. The REMARK guidelines for the characterization of bio-markers[@b11-bctt-9-415] and the international precepts of ethics in research and of good clinical practice were followed.

Clinical and histopathological characterization
-----------------------------------------------

A description of this study cohort has been published previously.[@b12-bctt-9-415] All the patients were interviewed to provide information on their clinical history and lifestyle habits. The variables considered for clinical history were age at diagnosis, menopausal status, and comorbidities, which were defined as any preexisting chronic condition under medical treatment, with the exception of obesity, which was defined based on the body mass index. Hypertension was defined according to disease severity, as inferred by the prescribed antihypertensive therapy.[@b13-bctt-9-415] The lifestyle variables were alcohol drinking, defined according to the frequency of consumption, and smoking, classified as current, previous, or no habit, considering a minimum consumption of five packs (100 cigarettes).

Histopathological characterization of breast tumors was based on the 3rd edition of the World Health Organization Classification of Tumors[@b14-bctt-9-415] and on the Elston--Ellis histological grading system.[@b15-bctt-9-415] Data on hormone receptors and human epidermal growth factor receptor 2 (HER-2) status of breast tumors, according to immunohistochemical and fluorescence in situ hybridization analyses, were used for the surrogate classification of tumor subtypes.[@b16-bctt-9-415]

Immunohistochemistry, antibody validation, and scoring
------------------------------------------------------

All paraffin-embedded blocks were stained with hematoxylin and eosin to select the most representative specimen for each patient, which was processed as described previously.[@b17-bctt-9-415] ABCB1 detection was tested with three antihuman ABCB1 monoclonal antibodies, namely sc-13131, clone G-1 (Santa Cruz Biotechnology Inc, Dallas, TX, USA.); ab3083, clone 265/F4 (Abcam, Cambridge, UK); and NCL-PGLYm, clone 5B12 (Leica Biosystems Newcastle Ltd., Newcastle, UK), and then revealed with Novolink Polymer Detection System standard protocol (Leica Biosystems Newcastle Ltd.). The most sensitive antibody among these three was sc-13131, clone G-1 (dilution 1:10,000).

Although the G-1 specificity toward ABCB1 has already been shown,[@b18-bctt-9-415]--[@b21-bctt-9-415] validation experiments were conducted in this study, as recommended by the consensus for ABCB1 detection,[@b2-bctt-9-415],[@b5-bctt-9-415] using specimens from different nonmalignant human tissues. Liver, adrenal, and kidney proximal and distal tubules were used as positive controls,[@b22-bctt-9-415]--[@b24-bctt-9-415] whereas tonsils, epididymis, and kidney glomeruli were used as negative controls.[@b23-bctt-9-415]--[@b25-bctt-9-415] Because ABCB1 was expected to be detected in the biliary canaliculi,[@b23-bctt-9-415] liver samples were also stained with anti-CD10 antibody (clone 56C6; Leica Biosystems Newcastle Ltd.; diluted 1:200). Liver samples were positive for ABCB1 ([Figure 2A and B](#f2-bctt-9-415){ref-type="fig"}), with a distribution pattern similar to that observed with the anti-CD10 antibody ([Figure 2C and D](#f2-bctt-9-415){ref-type="fig"}). The cross-reaction against ABCB4/MDR3 was investigated using human tonsils and kidney. Tonsils and kidney glomeruli showed no immunostaining ([Figure 2E--G](#f2-bctt-9-415){ref-type="fig"} \[arrows\]), indicating the absence of G-1 antibody cross-reaction toward ABCB4 (formerly known as MDR3).[@b26-bctt-9-415],[@b27-bctt-9-415] Proximal and distal kidney tubules, which express ABCB1,[@b24-bctt-9-415] showed positive staining ([Figure 2G and H](#f2-bctt-9-415){ref-type="fig"}), whereas kidney glomeruli (arrows in [Figure 2G](#f2-bctt-9-415){ref-type="fig"}), which express only ABCB4,[@b27-bctt-9-415] were negative ([Figure 2G and H](#f2-bctt-9-415){ref-type="fig"}), confirming the absence of cross-reactivity against ABCB4/MDR3.

Because of the observed intratumoral variability in ABCB1 staining in breast tumors ([Figure 2I and J](#f2-bctt-9-415){ref-type="fig"}), the individual quantification included the whole area of a representative tumor slide and was based on the two previously published scoring methods: a continuous scale (CS)[@b28-bctt-9-415] and a categorical score,[@b29-bctt-9-415] both of which consider the percentage of immunostained cells and the intensity of the reaction.

The CS was calculated as follows: CS = (%~weak~ × 1) + (%~moderate~ × 2) + (%~strong~ × 3).[@b28-bctt-9-415] The intensity of ABCB1 staining was rated as follows: negative (complete absence of cellular reaction), weak (diffuse and mild reaction in cytoplasm, with no detectable reaction in cell membranes), moderate (detectable reaction in both cytoplasm and plasma membrane), or strong (strong in both cytoplasm and plasma membrane). Nuclear reaction was not considered.

The categorical score, or immunoreaction score (IRS) was defined by the following equation: IRS = (positivity score) × (intensity score).[@b29-bctt-9-415] The positivity score was attributed 1 to 4, according to the percentage of positive cancer cells: 1 (1%--9%), 2 (10%--49%), 3 (50%--79%), or 4 (80%--100%). The intensity score ranged 0--3: negative (0), weak (1), moderate (2), or strong (3). Breast tissues were considered positive for ABCB1 when the IRS was ≥4, meaning that at least 10% of the cells presented moderate staining.[@b29-bctt-9-415]

All the slides were blindly evaluated by a trained PhD student (JMAD) and a pathologist (GMV).

Genotyping analyses
-------------------

Genomic DNA was extracted from peripheral blood samples (3 mL) by using the Blood Genomic Prep Mini Spin Kit (GE Heathcare, Buckinghamshire, UK). Genotyping analyses were conducted by using TaqMan real-time polymerase chain reaction (RT-PCR) assays in an ABI PRISM 7500 Sequence Detector System (Applied Biosystems, Foster City, CA, USA). Each reaction contained 1 µL of genomic DNA (20 ng/µL); 0.5 µL of probe, either C_7586662_10 for rs1128503 or C\_\_7586657_20 for rs1045642 (Applied Biosystems); 5µL of Genotyping Master Mix (Applied Biosystems); and 3.5 µL of water. All the experiments were carried out in 96-well plates, including a nontemplate control and at least two positive controls.

Quantification of ABCB1 mRNA
----------------------------

Fresh specimens of excised breast tumors were dissected by clinical pathologists, frozen in liquid N~2~, and stored at Banco Nacional de Tumores (BNT/INCA). Frozen sections of breast tumors were used for RNA isolation by using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The RNA samples were stored in RNase-free distilled water at −80°C, and the cDNA was synthesized by using 2 µg of RNA, with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems), according to the manufacturer's instructions.

The relative quantification (RQ) of *ABCB1* transcripts was performed by using by using TaqMan quantitative real-time PCR (qRT-PCR) assays, in an ABI PRISM 7500 Sequence Detector System (Applied Biosystems). Each reaction contained cDNA templates (40 ng), 10 µL of reaction mix containing 5 µL TaqMan Gene Expression Master Mix, and TaqMan probes (Applied Biosystems), which were as follows: *ABCB1* Hs01067802_m1\* (with FAM™), peptidylprolyl isomerase A (*PPIA*) Hs00216455_ml (with VIC^®^), used as reference gene. The thermal cycling conditions comprised an initial denaturation step at 95°C for 10 minutes, followed by 40 cycles of 95°C denaturation for 15 seconds, and annealing at 60°C for 1 minute. The experiments were carried out in 96-well plates, including a nontemplate control and a reference sample, consisting of cDNA obtained from a commercial human mammary gland (HMG) total RNA (Clontech Laboratories, Mountain View, CA, USA). The RQ of *ABCB1* mRNA was calculated as follows: RQ = 2^−∆∆Ct^, where ∆∆*Ct* = ∆*Ct~ABCB1~* − ∆*Ct*~HMG~, with ∆*Ct~ABCB1~* = *Ct~ABCB1~* − *Ct~PPIA~* and ∆*Ct*~HMG~ = *Ct*~HMG~ − *Ct~PPIA~*. All the data were generated in triplicates and expressed as median with their respective 95% confidence intervals (CI).

Characterization of outcomes in patients with breast cancer
-----------------------------------------------------------

Breast cancer progression was characterized by locoregional or contralateral recurrence or distant metastasis. New primary cancer lesions or deaths unrelated to breast cancer progression were censored. The patients were considered disease-free if they had no imaging diagnosis of disease progression or suggestive clinical symptoms up till their last medical consult. Because this is an ongoing cohort, the survival analysis was limited to 2 years of follow-up, which was available for all the patients.

Statistical analyses
--------------------

A descriptive study was conducted. Clinical and histopathological variables were categorized and expressed as number and relative frequencies. The association between IRS and *ABCB1* genotypes and clinical or histopathological variables was evaluated by using the *c*^2^ test. Individual variables were tested for linear-by-linear associations, with calculation of trend significances (*p*trend\<0.05) and categorized for better or worse prognosis, with the calculation of the odds ratios (ORs) and respective 95% CI. These variables were also compared for the continuous scale by using Mann--Whitney *U* test or Kruskal--Wallis test. Wald *c*^2^ test was used to identify independent predictors (*p*\<0.05), which were used for the calculation of the corresponding adjusted ORs (OR~adj~). The final regression model was tested with the Hosmer--Lemeshow test. All the statistical analyses were conducted by using IBM SPSS Version 20 for Windows (IBM Corp., Armonk, NY, USA) or GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA).

Disease-free survival curves were estimated by using the Kaplan--Meier product-limit method, and the impact of the individual variables was estimated by using log-rank analysis (*p*\<0.05). The significant covariates were included in multivariate Cox proportional hazards regression with the calculation of adjusted hazard ratios (HR~adj~) and respective 95% CIs.

Survival analyses were also performed by using *ABCB1* expression data obtained from publically available gene expression array databases. Two web platforms were evaluated: ProgGeneV2.0,[@b30-bctt-9-415] which comprises several independent breast cancer cohorts (only cohorts with at least 200 breast cancer patients were selected), and the Gene Expression Omnibus deposited data (<https://www.ncbi.nlm.nih.gov/geo/>), which was assessed via the online software KM plotter ([www.kmplot.com](http://www.kmplot.com)),[@b31-bctt-9-415] by using the filter for breast cancer and information regarding *ABCB1*. In both the platforms, the median value of *ABCB1* mRNA was used as a cutoff value to categorize *ABCB1* tumoral expression as "low" or "high".

Results
=======

Characterization of patients with breast cancer
-----------------------------------------------

[Table 1](#t1-bctt-9-415){ref-type="table"} presents the main clinical and histopathological characteristics of the breast cancer patients (n=712) and the allelic and genotypic distribution of rs1128503 (*ABCB1* C1236T) and rs1045642 (*ABCB1* C3435T).

After surgery, most patients received adjuvant protocols, including chemotherapy (61.4%), hormonal therapy (12.9%), hormonal therapy plus radiotherapy (10.8%), or radiotherapy alone (5.8%). The remaining 9.1% of the patients were clinically followed up with no secondary intervention. The main protocol for adjuvant chemotherapy, comprising 89% of cases, was three cycles of cyclophosphamide, doxorubicin, and 5-fluorouracil, followed by three cycles of docetaxel.[@b32-bctt-9-415],[@b33-bctt-9-415]

Immunohistochemical characterization of ABCB1 in breast cancer
--------------------------------------------------------------

[Figure 3](#f3-bctt-9-415){ref-type="fig"} shows ABCB1 immunostaining in the breast, including breast tumors ([Figure 3A--H](#f3-bctt-9-415){ref-type="fig"}) and normal mammary tissues from women without breast cancer ([Figure 3I and J](#f3-bctt-9-415){ref-type="fig"}). [Figure 3A and B](#f3-bctt-9-415){ref-type="fig"} illustrates fully negative reactions, whereas [Figure 3C--H](#f3-bctt-9-415){ref-type="fig"} shows a gradation of the immunostaining, which was graded as weak ([Figure 3C and D](#f3-bctt-9-415){ref-type="fig"}), moderate ([Figure 3E and F](#f3-bctt-9-415){ref-type="fig"}), or strong ([Figure 3G and H](#f3-bctt-9-415){ref-type="fig"}). Nonmalignant mammary tissue adjacent to the tumor area (n=606) showed positive reaction for ABCB1 in mammary ducts and acini (98.8% of cases), even when tumor staining was negative ([Figure 3A and B](#f3-bctt-9-415){ref-type="fig"}). The absence of ABCB1 in both the cancer cells and adjacent non-malignant breast tissue occurred in only five patients (0.8% of all tumor samples). All the cases of benign lesions (n=28) were homogeneously positive for ABCB1, with strong immunostaining in all mammary ducts and acini.

[Figure 4](#f4-bctt-9-415){ref-type="fig"} shows the distribution of ABCB1 immunostaining scores in the cohort. [Figure 4A](#f4-bctt-9-415){ref-type="fig"} presents a bar graph of the IRSs, whereas [Figure 4B](#f4-bctt-9-415){ref-type="fig"} is a histogram of the CS. According to the IRSs, 86.3% of breast tumors were positive for ABCB1 (IRS ≥4), and 71% presented high immunostaining scores (IRS ≥8). The histogram of the CS does not fit into a normal distribution (*p*\<0.001; D'Agostino--Pearson normality test), and 71% of tumors had high CS values (≥150).

Association between ABCB1 mRNA and ABCB1 protein levels in breast tumors
------------------------------------------------------------------------

[Figure 5](#f5-bctt-9-415){ref-type="fig"} depicts the association between *ABCB1* mRNA and ABCB1 protein levels in breast tumors. The stratification of tumors according to their IRSs, as positive or negative for ABCB1, indicates a significant difference in the levels of *ABCB1* mRNA ([Figure 5A](#f5-bctt-9-415){ref-type="fig"}), which were, on average, \~2 times higher among ABCB1 positive tumors. However, the analysis of individual data on *ABCB1* mRNA and on ABCB1 protein levels (evaluated as CS) indicates no linear correlation ([Figure 5B](#f5-bctt-9-415){ref-type="fig"}) and points to a large variability in the distribution of *ABCB1* mRNA in breast tumors. In order to explore the possible causes of such variability, the influence of *ABCB1* SNPs was investigated. [Figure 5C](#f5-bctt-9-415){ref-type="fig"} indicates a significant decrease in *ABCB1* mRNA levels among carriers of the variant homozygous *ABCB1* 1236TT (rs1128503), as compared to the other two groups of genotypes. The SNP rs1045642, however, showed no influence on the amounts of *ABCB1* mRNA in breast tumors ([Figure 5D](#f5-bctt-9-415){ref-type="fig"}).

Influence of clinical and histopathological parameters on ABCB1 expression in breast tumors
-------------------------------------------------------------------------------------------

Patients with positive or negative ABCB1 immunostaining in breast tumors were compared with regard to clinical, genetic, and histopathological variables. The conditions significantly associated with negative ABCB1 were hypertensive status, tumor size \>2 cm, low lymph node status (pN0 or pN1), early tumor stage (I or II), negative estrogen receptor (ER) status, negative progesterone receptor (PR) status, and triple-negative subtype ([Table 2](#t2-bctt-9-415){ref-type="table"}).

According to the final multivariate model ([Table 3](#t3-bctt-9-415){ref-type="table"}), hypertensive status, large tumor size, low lymph node status, and triple-negative subtype were independently associated with ABCB1 negativity.

Because all hypertensive patients were under pharmacological treatment, the effect of antihypertensive drugs on ABCB1 immunostaining was investigated ([Table 4](#t4-bctt-9-415){ref-type="table"}). No significant associations were found for individual drugs or their pharmacological groups. However, ABCB1 positivity was lower in more severe cases (*p*~trend~\<0.001).

Influence of decreased ABCB1 expression on disease-free survival of patients with breast cancer
-----------------------------------------------------------------------------------------------

[Figure 6](#f6-bctt-9-415){ref-type="fig"} shows the influence of *ABCB1* expression on the 2-year disease-free survival of patients with breast cancer. The results indicated that the loss of *ABCB1* expression (IRS ≤4) favors early-onset breast cancer progression when evaluated for all the patients in the cohort ([Figure 6A](#f6-bctt-9-415){ref-type="fig"}) or for patients with triple-negative tumors ([Figure 6B](#f6-bctt-9-415){ref-type="fig"}). The impact of the loss of *ABCB1* expression on the rates of breast cancer progression was maintained after adjustment for other prognostic factors, that is, *HER-2*-like or triple-negative subtypes, staging group ≥II, histological grade 3, and the use of chemotherapy (HR =3.5; 95% CI =1.2--9.9) when all the tumors were considered; or staging group ≥II and histological grade 3 for triple-negative tumors (HR =11.4; 95% CI =1.3--100.7).

The influence of *ABCB1* expression on the 2-year disease-free survival of patients with breast cancer was also evaluated, considering *ABCB1* mRNA levels in tumors that could be fresh-frozen at the time of the excision surgery (n=154). A significant difference was detected (*p* log-rank =0.012), with the patients whose tumors had low *ABCB1* mRNA presenting worse cumulative survival than the patients with high *ABCB1* mRNA ([Figure 6C](#f6-bctt-9-415){ref-type="fig"}). However, because of the lack of events in the group with high mRNA, the calculation of the HR was compromised. Therefore, the survival analysis based on *ABCB1* mRNA was extended to publically available databases from breast cancer cohorts ([Tables 5](#t5-bctt-9-415){ref-type="table"} and [6](#t6-bctt-9-415){ref-type="table"}). The results obtained with these cohorts confirmed that low *ABCB1* mRNA is associated with worse survival outcomes (both disease-free survival and overall survival), either when considered for all the patients with adjustment for ER positivity or when evaluated only among ER negative subtype or among the basal subtype ([Table 6](#t6-bctt-9-415){ref-type="table"}).

Finally, the influence of *ABCB1* SNPs on the 2-year disease-free survival was also evaluated, but no significant association with early-onset breast cancer progression was detected either for rs1128503 (*p* log-rank =0.57) or for rs1045642 (*p* log-rank =0.55).

Discussion
==========

The present work characterized the *ABCB1* expression in breast cancer in comparison with nonmalignant breast tissue. All methodological recommendations for the detection of ABCB1 by immunohistochemistry[@b2-bctt-9-415],[@b4-bctt-9-415] were followed. First, three different antibody clones (ie, G-1, 5B12, 265/F4) were tested. The most sensitive clone was G-1, whose specificity towards ABCB1 was confirmed ([Figure 2](#f2-bctt-9-415){ref-type="fig"}). Second, breast tumors were processed immediately after resection, by using buffered formalin. Third, a polymer-based kit was used to improve antibody sensitivity.[@b42-bctt-9-415] Fourth, two different scoring methods[@b28-bctt-9-415],[@b29-bctt-9-415] were used. Finally, *ABCB1* mRNA was quantified in freshly frozen tumors, testing a second parameter of *ABCB1* expression. In addition, the study was conducted in a prospective manner, by using all the available samples from a relatively large cohort of patients (656 tissue samples from 712 patients). For comparison, a literature review on ABCB1 detection by immunohisto-chemistry in breast cancer retrieved only nine studies with ≥100 patients.[@b17-bctt-9-415],[@b29-bctt-9-415],[@b43-bctt-9-415]--[@b49-bctt-9-415]

The results on *ABCB1* expression in breast tumors indicated high interindividual variability, considering both the percentage of immunostained cells and the intensity of the immunostaining reaction. A meta-analysis conducted by Trock et al,[@b2-bctt-9-415] comprising 31 studies, also indicated a high heterogeneity in ABCB1 positivity, with a weighted average value of 48.5% (95% CI =42--55.0), and a trend for higher values in more recent studies. For example, in two recent retrospective studies, the reported ABCB1 detection was 42% in 104 patients[@b29-bctt-9-415] or 66% in 177 patients.[@b48-bctt-9-415]

The evaluation of nonmalignant mammary tissues indicated the presence of ABCB1 in all cases of benign breast lesions, as well as in the normal ducts and acini of 98.8% of breast cancer samples. Such results are in agreement with the findings of Pavelic et al,[@b50-bctt-9-415] who described ABCB1 immuno-reactivity in normal ductal epithelia using four independent antibodies. Likewise, Scala et al[@b51-bctt-9-415] showed that \>80% of normal breast ductal epithelium stained positively for ABCB1, with staining being confined to the luminal surface.[@b51-bctt-9-415] Considering that most breast tumors have a ductal origin, it seems that ABCB1 detection in breast carcinoma is a consequence of constitutive *ABCB1* expression in the breast, rather than an acquired or rare phenotype. However, Zhu et al[@b52-bctt-9-415] found higher *ABCB1* expression in breast cancer tissues (57.3%) compared with adjacent noncancerous tissues (5.0%).

As an attempt to investigate the individual aspects that may modulate *ABCB1* expression in breast tumors, mRNA levels and *ABCB1* genotypes were evaluated. *ABCB1* mRNA levels were reduced in tumors from patients carrying the TT genotype of rs1128503, although no significant effect was detected in the final protein levels. There are no previous reports on the effect of rs1128503 in breast tumors, but a recent review indicated no effect on ABCB1 protein levels or activity in acute myeloid leukemia.[@b53-bctt-9-415] With regard to rs1045642, previous studies suggest that the TT genotype might lead to decreased *ABCB1* mRNA levels in mammary carcinoma cell lines,[@b54-bctt-9-415] or in breast tumor,[@b55-bctt-9-415] which was not confirmed by the present study. Taken together, these results highlight the risks of using mRNA quantification to infer protein levels or activity. Accordingly, there seems to be a posttranscriptional regulation of *ABCB1* expression, possibly mediated by microRNAs.[@b56-bctt-9-415]

The evaluation of ABCB1 immunostaining according to histopathological variables indicated lower expression among tumors with large size, low lymph node status, or triple-negative subtype. Some other authors also found positive associations between ABCB1 in breast tumors and lymph node metastases[@b29-bctt-9-415],[@b52-bctt-9-415],[@b57-bctt-9-415],[@b58-bctt-9-415] or positive ER status.[@b43-bctt-9-415],[@b45-bctt-9-415] However, Kuroda et al[@b49-bctt-9-415] found higher ABCB1 immunostaining with the reduction or loss of ER, PR, and HER-2. They identified ABCB1 in 29 (59.2%) of 49 basal-like carcinomas, characterized by the presence of cytokeratins 5/6, 14, or 17, as compared to 85 (30.6%) among 278 non-basal-like carcinomas. In the present study, the expression of cytokeratins was not evaluated. Thus, *ABCB1* expression according to the luminal or basal origin of breast carcinoma or among the triple-negative basal-subtypes could not be inferred.

With regard to the association of decreased *ABCB1* expression with hypertension, an experimental model of spontaneously hypertensive rats suggested lower ABCB1 activity in the kidneys and in peripheral blood mononuclear cells.[@b59-bctt-9-415] In addition, ABCB1 protein levels were also diminished in the kidneys of rats submitted to high-sodium diet[@b9-bctt-9-415],[@b60-bctt-9-415] or to adrenalectomy.[@b9-bctt-9-415] Because a mineralocorticoid receptor[@b61-bctt-9-415] and a tissue renin--angiotensin system[@b62-bctt-9-415] have been identified in normal and malignant breast tissues, it is possible that this pathway may modulate *ABCB1* expression in breast cancers and that a disruption of the renin--angiotensin system in the malignant tissue[@b62-bctt-9-415] may contribute to lower *ABCB1* expression in some cases.

Finally, the analysis of breast cancer outcomes suggested that the loss of *ABCB1* expression is associated with early-onset disease progression, especially among patients with triple-negative tumors. There is no presumed causal mechanism to justify how the loss of ABCB1 in breast cancer would favor cell survival, proliferation, migration, or invasion. Instead, the recognized actions of ABCB1 as a physiological regulator of cell cycle and apoptosis and of the lipid turnover and maintenance of membrane structure are expected to protect cancer cells from death.[@b63-bctt-9-415] It is believed that the loss of ABCB1 in breast cancer tissue might be a consequence of the genomic instability in cancer cells, especially among triple-negative tumors, which also lack other regulatory proteins, including the ER and HER-2, rather than a specific adaptation leading to a more aggressive phenotype.

The results obtained with publically available databases corroborated the findings of the present study and suggested that low *ABCB1* mRNA may predict shorter disease-free survival and overall survival even when considering only patients with triple-negative clusters, such as the basal-type, which poses the greatest challenge for treatment because of its aggressive clinical course and lack of targeted therapy.[@b64-bctt-9-415] Taken together, the current results indicated that negative or low *ABCB1* expression in breast tumors, rather than being beneficial due to a possible reduction of drug efflux, seems to indicate a more aggressive phenotype, which may occur in luminal tumors, but is more frequent among triple-negative tumors.

Conclusion
==========

In conclusion, the study results point to important paradigm changes in the concept of chemoresistance in breast cancer: 1) *ABCB1* seems to be constitutively expressed in the normal mammary tissue, being maintained, rather than acquired, in nonmalignant lesions and in most cases of breast cancer; 2) ABCB1 protein levels might be downregulated in some breast cancers, especially in triple-negative tumors, or as a consequence of systemic arterial hypertension, although the prognostic impact of such association is yet to be determined; and 3) the absence of ABCB1 in triple-negative tumors might contribute to identify a subgroup with worse prognosis.
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![Flowchart of the study cohort.\
**Abbreviations:** qRT-PCR, quantitative real-time polymerase chain reaction; IHC, immunohistochemistry.](bctt-9-415Fig1){#f1-bctt-9-415}

![**I**mmunohistochemical evaluation of ABCB1 in human tissues.\
**Notes:** The right column indicates 100× magnification, and the left column indicates 400× magnification. (**A** and **B**) Immunostaining of ABCB1 in the liver; (**C** and **D**) immunostaining pattern control of a specific marker for biliary canaliculi (CD10) in the liver; (**E** and **F**) negative controls of ABCB1 in tonsils; (**G** and **H**) controls of ABCB1 in the kidney -- proximal (strong reaction) and distal (weak reaction) tubules are positive controls, and glomeruli (black arrows) are negative controls; (**I** and **J**) immunostaining of ABCB1 in a breast cancer sample, showing regions with positive (brown) and negative reactions (circumvented by a red line), as they were seen in the slide (**I**) or side-by-side for better visualization (**J**). All the sections were counterstained with hematoxylin (blue staining).\
**Abbreviation:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1.](bctt-9-415Fig2){#f2-bctt-9-415}

![Photomicrographs of ABCB1 immunostaining in human mammary tissue samples showing different immunoreaction intensities.\
**Notes:** (**A**--**H**) Breast cancer samples: (**A** and **B**) negative; (**C** and **D**) weak; (**E** and **F**) moderate; (**G** and **H**) strong immunostaining; (**I** and **J**) nonmalignant mammary tissues with strong immunostaining.\
**Abbreviation:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1.](bctt-9-415Fig3){#f3-bctt-9-415}

![Distribution of ABCB1 immunoreaction scores in human breast tumors.\
**Notes:** (**A**) immunoreaction score (IRS); (**B**) continuous scale (CS).\
**Abbreviation:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1.](bctt-9-415Fig4){#f4-bctt-9-415}

![Distribution of *ABCB1* mRNA levels in human breast tumors.\
**Notes:** *ABCB1* mRNA levels are shown according to the ABCB1 IRS (**A**); ABCB1 CS (**B**); rs1128503 genotypes (**C**); and rs1045642 genotypes (**D**). \**p*\<0.5; \*\**p*\<0.01. Both in Mann-Whitney test.\
**Abbreviations:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1; CS, continuous scale; IRS, immunoreaction score; RQ, relative quantification.](bctt-9-415Fig5){#f5-bctt-9-415}

![Two-year disease-free survival curves of patients with breast cancer based on either ABCB1 protein levels (IRS) or dichotomized mRNA expression.\
**Notes:** (**A**) IRS on all tumors; (**B**) IRS on triple-negative tumors; (**C**) mRNA levels on all tumors. *p* log-rank and HR with respective 95% CIs are provided for the comparison between positive IRS (green on **A** and **B**) and negative IRS (blue on **A** and **B**) or between mRNA levels above the median (high in green on **C**) or below the median (low in blue on **C**).\
**Abbreviations:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1; CI, confidence interval; CS, continuous scale; HR, hazard ratio; IRS, immunoreaction score.](bctt-9-415Fig6){#f6-bctt-9-415}

###### 

Description of individual features in breast cancer patients

  Clinical features           n     \%     Histopathological features   n     \%
  --------------------------- ----- ------ ---------------------------- ----- ------
  Age at diagnosis                         Histological type                  
   24--34 years               15    2.1     Ductal invasive             597   83.9
   35--44 years               82    11.5    Lobular invasive            40    5.6
   45--54 years               181   25.4    Ductal in situ              45    6.3
   55--64 years               208   29.2    Lobular in situ             3     0.4
   ≥65 years                  226   31.7    Others                      27    3.8
  Color                                     Missing                     1     
   White                      320   45.7   Tumor size (pT)                    
   Brown                      268   38.3    pTis (in situ)              48    6.7
   Black                      88    12.6    pT1 (≤2 cm)                 321   45.1
   Others                     24    3.4     pT2 (2--5 cm)               309   43.4
   Missing                    12            pT3 (\>5 cm)                21    2.9
  Menopausal status                         Missing                     13    
   Premenopausal              179   25.6   Lymph node status (pN)             
   Postmenopausal             521   74.4    pN0 (none)                  421   59.6
   Missing                    12            pN1 (≤3 positive nodes)     177   25.1
  Smoking status                            pN2 (4--9 positive nodes)   66    9.3
   Nonsmoker                  464   66.2    pN3 (≥10 positive nodes)    42    5.9
   Former smoker              173   24.7    Missing                     6     
   Current smoker             64    9.1    Tumor grade (G)                    
   Missing                    11            G1                          83    12.7
  Alcohol consumption                       G2                          261   39.9
   Never                      384   56.0    G3                          310   47.4
   Rare (\<3 days/week)       212   30.9    Missing                     58    
   Frequent (\>3 days/week)   90    13.1   Stage grouping                     
   Missing                    26            0                           46    6.6
  Comorbidities                             I                           227   32.5
   None                       91    12.8    II                          312   44.7
   Hypertension               377   53.3    III                         113   16.2
   Obesity                    159   28.7    Missing                     14    
   Diabetes mellitus          104   14.9   ER status                          
  BMI (Kg/m^2^)                             Negative                    111   16.2
   \<18.4                     6     1.0     Positive                    575   83.8
   18.5--24.9                 164   28.4    Missing                     26    
   25--29.9                   248   43.0   PR status                          
   \>30.0                     159   27.6    Negative                    197   28.8
   Missing                    135           Positive                    488   71.2
  *ABCB1* genotypes                         Missing                     27    
   rs1128503 (C1236T)                      HER-2 status                       
    CC                        222   39.7    Negative                    515   81.1
    CT                        269   48.1    Positive                    103   16.2
    TT                        68    12.2    Undetermined                17    2.7
                                            Missing                     77    
   rs1045642 (C3435T)                      Tumor subtype                      
    CC                        227   39.3    Luminal A                   395   63.2
    CT                        257   44.5    Luminal B                   130   20.8
    TT                        94    16.3    HER-2-like                  38    6.1
                                            Triple-negative             62    9.9
                                            Missing                     87    

**Notes:** n=712. Data are expressed as the number and percentage of patients in each category.

**Abbreviations:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1; BMI, body mass index; ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; PR, progesterone receptor.

###### 

Significant associations between individual features and ABCB1 expression in breast tumors

  Individual features      IRS status   CS                                  
  ------------------------ ------------ ---------------- ------- ---------- -------------------------------------------------------
  Hypertension                                                              
   No                      1                             200     160--250   \<**0.001**
   Yes                     **0.51**     **0.32--0.82**   180     103--239   
  Tumor size (pT)                                                           
   pT1                     1                             200     135--269   **0.003**
   pT2 + pT3               **0.59**     **0.37--0.95**   185     155--250   
  Lymph node status (pN)                                                    
   pN0 + pN1               1                             190     123--294   **0.001**
   pN2 + pN3               **3.64**     **1.44--9.19**   202.5   120--240   
  Stage grouping                                                            
   I + II                  1                             190     120--240   \<**0.001**
   III                     **3.15**     **1.34--7.43**   210     170--270   
  ER status                                                                 
   Positive                1                             195     145--250   \<**0.001**
   Negative                **0.38**     **0.23--0.65**   160     70--220    
  PR status                                                                 
   Positive                1                             200     150--250   \<**0.001**
   Negative                **0.47**     **0.30--0.76**   177.5   90--220    
  Tumor subtype                                                             
   Luminal A               1                             195     150--250   
   Luminal B               0.86         0.46--1.62       190     143--245   \<**0.001**[a](#tfn4-bctt-9-415){ref-type="table-fn"}
   HER-2-like              0.82         0.27--2.47       195     140--238   
   Triple-negative         **0.21**     **0.11--0.39**   125     20--193    

**Notes:** n=656. Data are expressed as the OR, based on the IRS status, or as the median value of the CS, for each category, with the respective 95% CIs. Statistically significant differences are presented in bold characters.

*p*-value of Kruskal--Wallis test.

**Abbreviations:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1; CI, confidence interval; CS, continuous scale; ER, estrogen receptor; IRS, immunoreaction score; HER-2, human epidermal growth factor receptor 2; OR, odds ratio; *p*M-W, *p*-value for the Mann--Whitney test; PR, progesterone receptor.

###### 

Multivariate model of ABCB1 positivity according to clinical and histopathological features of breast tumors

  Individual features      Adjusted OR   Adjusted 95% CI   Wald coefficient   *p*H-L
  ------------------------ ------------- ----------------- ------------------ --------
  Triple-negative                                                             
   Positive                0.24          0.13--0.45        19.6               
  Hypertension                                                                
   Yes                     0.42          0.24--0.73        9.7                0.298
  Lymph node status (pN)                                                      
   pN0 + pN1               0.27          0.10--0.71        7.1                0.552
  Tumor size (pT)                                                             
   pT2 + pT3               0.55          0.32--0.93        4.9                0.139

**Abbreviations:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1; CI, confidence interval; OR, odds ratio; *p*H-L, *p*-value for the Hosmer--Lemeshow test.

###### 

Influence of hypertension severity and treatment on ABCB1 positivity in breast tumors

  Individual features                                                 IRS status   CS                                  
  ------------------------------------------------------------------- ------------ ---------------- ------- ---------- -------------------------------------------------------
  Hypertension treatment                                                                                               
   Normotensive                                                       1                             200     160--250   \<**0.001**[a](#tfn8-bctt-9-415){ref-type="table-fn"}
   Monotherapy                                                        0.76         0.40--1.43       180     125--243   
   Combined therapy                                                   0.58         0.33--1.03       188     110--236   
   Resistant hypertension[b](#tfn9-bctt-9-415){ref-type="table-fn"}   **0.17**     **0.08--0.35**   160     45--225    
  Diuretics (n)                                                                                                        
   No (168)                                                           1                             180     103--240   0.890
   Yes (180)                                                          0.57         0.312--1.02      185     103--230   
  ACE inhibitors (n)                                                                                                   
   No (190)                                                           1                             185     108--245   0.432
   Yes (154)                                                          1.09         0.61--1.92       180     100--226   
  Beta-blockers (n)                                                                                                    
   No (227)                                                           1                             185     110--240   0.234
   Yes (117)                                                          0.68         0.38--1.22       180     85--230    
  ATR1 antagonists (n)                                                                                                 
   No (257)                                                           1                             180     110--230   0.967
   Yes (87)                                                           0.87         0.46--1.64       180     90--250    
  Calcium channel blockers (n)                                                                                         
   No (278)                                                           1                             180     100--236   0.657
   Yes (66)                                                           1.36         0.63--2.92       187.5   130--240   

**Notes:** n=344. Data are expressed as the OR, based on the IRS status, or as the median value of the CS, for each category, with the respective 95% CIs. Statistically significant differences are presented in bold characters. The number of patients (n) per group are given in parentheses.

*p*-value of Kruskal--Wallis test;

Classified according to Daughert.

**Abbreviations:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1; ACE, angiotensin converting enzyme; ATR1, angiotensin II receptor 1; CI, confidence interval; CS, continuous scale; IRS, immunoreaction score; OR, odds ratio; *p*M-W, *p*-value for the Mann--Whitney test.

###### 

Influence of ABCB1 mRNA status (low) on the disease-free survival of breast cancer cohorts available at ProgGeneV2.0

  Study ID        n     Follow-up (years)   DFS                               OS                                Adjusting factor   Reference
  --------------- ----- ------------------- --------------------------------- --------------------------------- ------------------ -------------------
  NKI             295   16                  *p*\<0.0001; HR =1.5 (1.2--1.8)   *p*\<0.0002; HR =1.6 (1.2--1.9)   ER                 [@b57-bctt-9-415]
  GSE11121        200   16                  *p*\<0.01; HR =3.8 (1.4--10.0)    N/A                               None               [@b58-bctt-9-415]
  GSE4922_U133A   249   11                  *p*=0.003; HR =2.8 (1.4--5.6)     N/A                               ER                 [@b59-bctt-9-415]
  GSE22219        215   1                   *p*=0.003; HR =3.8 (1.6--9.1)     N/A                               ER and grade       [@b60-bctt-9-415]
  GSE17705        298   16                  *p*=0.001; HR =9.1 (2.3--33.3)    N/A                               None               [@b61-bctt-9-415]
  GSE2034         246   13                  *p*=0.6; HR =1.1 (0.7--2.0)       N/A                               ER                 [@b62-bctt-9-415]
  GSE3494_U133A   236   11                  N/A                               *p*=0.006; HR =3.6 (1.4--8.3)     ER and PR          [@b63-bctt-9-415]
  GSE21653        247   13                  N/A                               *p*=0.004; HR =1.7 (1.2--2.4)     ER                 [@b64-bctt-9-415]
  TCGA-BRCA       594   13                  N/A                               *p*=0.2; HR =1.12 (0.7--1.1)      ER and PR          [@b65-bctt-9-415]

**Notes:** Data were obtained from survival plots generated on ProgGeneV2.0 for cohorts with at least 200 patients.

**Abbreviations:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1; DFS, disease-fee survival (relapse-free or metastases-free, as available for each study); ER: estrogen receptor; HR, hazard ratio; N/A, not available; OS: overall survival; *p*, *p*-value for log-rank analysis; PR, progesterone receptor.

###### 

Influence of ABCB1 mRNA status (low) on the 5-year disease-free survival and overall survival of breast cancer cohorts available at the GEO database

  Subset of breast cancer patients   DFS                 OS
  ---------------------------------- ------------------- -------------------
  All                                                    
   n                                 3,951               1,402
   *p* log-rank                      1e--16              0.00025
   Hazard ratio                      1.89 (1.67--2.13)   1.64 (1.25--2.13)
  ER positive                                            
   n                                 2,061               548
   *p* log-rank                      0.0018              0.095
   Hazard ratio                      1.35 (1.12--1.64)   1.47 (0.93--2.33)
  ER negative                                            
   n                                 801                 251
   *p* log-rank                      0.00071             0.027
   Hazard ratio                      1.54 (1.19--1.92)   1.82 (1.06--3.13)
  Basal                                                  
   n                                 618                 241
   *p* log-rank                      2.4e--07            0.0081
   Hazard ratio                      2.00 (1.54--2.63)   2.17 (1.2--3.85)

**Notes:** Data were obtained from survival plots generated on KM plotter by using the filter for breast cancer. Cutoff values for low and high ABCB1 mRNA levels were set to the median.

**Abbreviations:** ABCB1, adenosine 5′-triphosphate--binding cassette subfamily B member 1; DFS, disease-fee survival; ER, estrogen receptor; GEO, the Gene Expression Omnibus; OS, overall survival.
